Just over 35,000 patients have been authorized to receive one of the four anti-Covid treatments approved in France alongside vaccination campaigns, health authorities announced on Thursday.
Read alsoSanofi's anti-Covid vaccine finally ready
"
Currently in France, four treatments are subject to early access for the care of people at high risk of a severe form of Covid-19 disease: Xevudy, Paxlovid, Ronapreve and Evusheld
", recalled in a press release.
the National Medicines Safety Agency (ANSM).
"
In total, more than 16,000 requests to treat patients (...) have been accepted for Ronapreve since the start of early access, and more than 14,000 (for) Evusheld
", detailed the agency.
"
For the two treatments (...) Xevudy and Paxlovid, authorized for early access at the start of 2022 and retaining neutralizing activity against the Omicron variant, 4,257 and 1,500 applications for use have respectively been authorized
", she continued, announcing that it would regularly update this balance sheet.
These treatments, which are synthetic antibodies with the exception of the Paxlovid pill from Pfizer, are aimed in particular at immunocompromised people, who are at high risk of developing a serious form even when they are vaccinated.
For one of them, Evusheld from AstraZeneca, it is even used instead of vaccination, considered ineffective for some patients.
The others are given as curative treatments to prevent progression to a serious form.
The case of Roche's Ronapreve is also specific: it is only approved against the Delta variant, now very much in the minority compared to Omicron against which this treatment appears ineffective.